Category: Alcon

  • PharmaShots Weekly Snapshots (November 08 – 12, 2021)

    Eisai Presents Results of Lecanemab in P-IIb Study 201 Study for the Treatment of Alzheimer’s Disease at CTAD 2021 Published: Nov 12, 2021 | Tags: Eisai, Lecanemab, P-IIb, Study 201 Study, Alzheimer’s Disease, CTAD 2021 Novo Nordisk’s Wegovy (semaglutide) Receives CHMP’s Recommendation for Approval to Treat Obesity Published: Nov 12, 2021 | Tags: Novo Nordisk, […]

  • Alcon to Acquire Ivantis for ~$475M

    Shots: Ivantis to receive $475M up front along with additional payments upon achievement of regulatory & commercial milestones. The transaction is expected to close in Q1’22 The acquisition expands Alcon’s surgical portfolio & uses the commercial execution expertise across cataract, refractive, retina & glaucoma. Hydrus Microstent is approved for use in conjunction with cataract surgery […]

  • Top 20 Medical Device Companies Based on 2020 Revenue

    The medical devices industry is a fast-growing market driven by the complex needs of patients encouraging life science companies to develop innovative therapies to improve health and QoL In 2020, the companies have shown growth resulted from a rise in the number of healthcare facilities, healthcare expenditure, technological advancements. Medtronic remains at the top of […]

  • Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza

    Shots: Novartis to receive $355M following the closure of acquisition, which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and strengthens its footprints in the US The companies will initiate a transition period where Novartis will continue to sell Simbrinza and transfer the profit to Alcon. Following the transition period, […]